ESMO 2017

Patients who received ipilimumab as adjuvant therapy had improved recurrent-free survival, but also

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

By

Andrea S. Blevins Primeau, PhD, MBA

September 6, 2017

Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.

Results from a small retrospective study showed that percutaneous microwave ablation (MWA) had a tec

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

By

Andrea S. Blevins Primeau, PhD, MBA

September 6, 2017

Adoptive cellular immunotherapy has not been widely used for cancer treatment.

Vaccine

Nivolumab Plus HPV-16 Vaccine are Promising in HPV-16+ Cancers

By

Andrea S. Blevins Primeau, PhD, MBA

September 6, 2017

Immune checkpoint inhibition may improve the efficacy of vaccine-induced T cells in incurable HPV genotype 16-positive cancer.

Next post in ESMO 2017

A pharmacist-led medication assessment demonstrated high prevalence of polypharmacy and potentially

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention